Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.

Open Access
Publisher Website
Google Scholar
Abstract
The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year. Clinical and laboratory assessments were made at four-weekly intervals over a period of 52 weeks. A statistically significant difference (p less than 0.05) in mean prednisolone dose was noted between the two groups at the end of 52 weeks, there being a fall in steroid requirement in the azathioprine treated group.